Research Article Details
| Article ID: | A26959 |
| PMID: | 19464069 |
| Source: | J Hepatol |
| Title: | Association between omental adipose tissue macrophages and liver histopathology in morbid obesity: influence of glycemic status. |
| Abstract: | BACKGROUND/AIMS: Recently we showed that macrophage accumulation in omental adipose tissue is associated with liver fibro-inflammation in morbidly obese subjects. Here, we evaluated the influence of glycemic status and extended the analysis to the spectrum of obesity-linked liver damage. METHODS: Liver biopsies, subcutaneous and omental adipose tissue were collected in 132 obese subjects during gastric bypass surgery. HAM56+ adipose tissue macrophages were counted in subjects classified by liver histopathology and by their degree of insulin resistance. RESULTS: In the whole population, the number of omental macrophages increased with the score of steatosis, the non-alcoholic fatty liver disease activity score, the stage of fibrosis and with fibro-inflammation index. None of these relationships were significant with subcutaneous macrophage count. In insulin-sensitive participants, omental macrophages accumulation was higher in subjects with high indexes of fibro-inflammation (p=0.012 vs. low indexes). In insulin-resistant including type 2 diabetic participants, omental macrophage count was higher both in subjects with high scores of steatosis and in subjects with high indexes of fibro-inflammation (p<0.05 vs. low scores). CONCLUSIONS: Macrophage accumulation in omental adipose tissue is associated with aggravated steatosis and fibro-inflammation in insulin-resistant obese subjects independently of altered glycemic status. |
| DOI: | 10.1016/j.jhep.2009.02.031 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |